The company’s partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung ...
The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...
Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, ...
AstraZeneca (AZN), and AbbVie (ABBV) are among the winners of positive drug recommendations in the EU this week. Read more ...
They are companies’ sales pitches meant to get patients to buy their products even if a different drug or no drug would ...
Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor ...
Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda ...
The media may not want to admit it, but Trump's results speak for themselves: lower prices, more transparency, and real ...
Foundation Medicine, Inc., a global, patient-focused precision medicine company , today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne ® CDx ...
The U.S. Supreme Court has declined to hear petitions from six major drugmakers challenging the Medicare Drug Price Negotiation Program, leaving in place lower court rulings that upheld the program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results